Editor Conflict of Interest Disclosures
A PDF of the Editors' conflict of interest disclosure information is available for download here.
Member, Board of Directors: Varian Biopharma
Consulting: Samus Therapeutics, Partner Therapeutics, Ascentage, Oncology Analytics
Honoraria: Pfizer, Genentech/Roche
Speakers' Bureau: Pfizer
Honoraria: Pfizer
Consulting or Advisory Role: UnitedHealthcare
Research Funding: Novartis
No conflicts to report
Honoraria: Prime Oncology, Elsevier, Itamar Medical
Consulting or Advisory Role: Monteris Medical, Incyte, AstraZeneca, Bristol-Myers Squibb, Abbvie
Research Funding: Novartis, TRACON Pharma, Novocure, Spectrum Pharmaceuticals, Lilly/ImClone, Boehringer Ingelheim
Honoraria: AstraZeneca, Eisai, Genentech/Roche, Ipsen, Puma, and Seattle Genetics
Consulting/Advisory: AstraZeneca, Eisai, Genentech/Roche, Ipsen, Puma Biotechnology, and Seattle Genetics
Institutional Research Funding: G1-Therapeutics, Lilly, Merck, Nektar, Puma Biotechnology, Seattle Genetics, and Tesaro
Intellectual Property: Jones and Bartlett and UptoDate.com
Travel, Accommodations, or other Expenses: Eisai
No conflicts to report
Consulting or Advisory Role: INC Research and Cyt RX, Marathon Pharma, Morphotek
No conflicts to report
No conflicts to report
Consulting or Advisory Role: Bristol Myers Squibb, Immatics, Instil Bio, Iovance, Lyell Immunopharma, Novartis, and Pfizer
Research funding: Iovance
No conflicts to report
Consultant: Intercept Health and UpScript Pager
No conflicts to report
Employment: Flatiron Health
Patents, Royalties, & Other Intellectual Property: Patents pending relating to inventions as employee of NCCN
Other Relationships: National Comprehensive Cancer Network
Stock/Honoraria: Curesponse, Osel, Pionyr, Precede Bio, and Tempest Therapeutics
Consulting or Advisory Role: Alkermes, Analysis Group, Aravive, Arcus Biosciences, ASCO, AstraZeneca, Bayer, Bristol Myers Squibb, Clinical Care Options, Eisai, EMD Serono, ESMO, Exelixis, Foundation Medicine, Gilead Sciences, GlaxoSmithKline, Harborside Press, Infinity Pharmaceuticals, Ipsen, Janssen Oncology, Kanaph Therapeutics, The Lancet Oncology, Eli Lilly, Merck, MJH Life Sciences, Navinata Health, NCCN, NiKang Therapeutics, Novartis, Peloton Therapeutics, Pfizer, PlatformQ Health, Precede Bio, Prometheus, Roche/Genentech, Sanofi/Aventis, Scholar Rock, Tempest Therapeutics, The New England Journal of Medicine, and UpToDate
Research Funding: Agensys, Arcus Biosciences, AstraZeneca, AVEO, Bayer, Bristol Myers Squibb, Calithera Biosciences, Eisai, Exelixis, GlaxoSmithKline, Ipsen, Merck, NiKang Therapeutics, Novartis, Peloton Therapeutics, Pfizer, Roche, Roche/Genentech, Seattle Genetics/Astellas, Takeda, and TRACON Pharma
Patents/Royalties: Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy, ctDNA technologies, and PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response
Travel Expenses: Alexion Pharmaceuticals, Allegiant, Analysis Group, AstraZeneca, Bayer, Bristol Myers Squibb, Cerulean Pharma, Clinical Care Options, Corvus Pharmaceuticals, Eisai, EMD Serono, ESMO, Exelixis, Foundation Medicine, GlaxoSmithKline, Harborside Press, HERON, Ipsen, Kidney Cancer Association, The Lancet Oncology, Eli Lilly, Lpath, Merck, MJH Life Sciences, Navinata Health, NCCN, Novartis, Peloton Therapeutics, Pfizer, PlatformQ Health, Prometheus, Roche/Genentech, Sanofi/Aventis, The New England Journal of Medicine, and UpToDate.
No conflicts to report
Leadership: Blueprint Medicines
Stock & Other Ownership Interests: Blueprint Medicines, G1 Therapeutics, Bessor Pharma, Caris Life Sciences, Champions Oncology, N-of-One
Consulting or Advisory Role: Bayer, Pfizer, Novartis, Lilly, EMD Serono, Sanofi, Janssen Oncology, PharmaMar, Daiichi Sankyo, Blueprint Medicines, Kolltan Pharmaceuticals, WIRB-Copernicus Group, ZIOPHARM Oncology, Polaris, Nektar, Genocea Biosciences, G1 Therapeutics, Caris Life Sciences, Adaptimmune, Eisai, Kyocera
Research Funding: Abbvie, Janssen Oncology
Patents, Royalties, & Other Intellectual Property: Patent on use of imatinib for GIST, receive minor royalty payment from Dana-Farber and Novartis
Consulting/Advisory: Array BioPharma, Bayer Schering Pharma, Foundation of Medicine, and Natera
Consulting or Advisory Role: AMAG Pharmaceuticals, ARIAD, Biodesix, Boehringer Ingelheim, Eisai, Gilead Sciences, Helsinn Therapeutics, Lilly, Roche/Genentech
Research Funding: Puma Biotechnology
No conflicts to report
Royalties: UpToDate
Consulting Fees: InformedDNA, Blue Note Therapeutics, and Roche
No conflicts to report
No conflicts to report
No conflicts to report
Stock and Other Ownership Interests: Bactonix
Honoraria: Bristol-Myers Squibb, Immunocore, Novartis, Pfizer, and Regeneron
Consulting or Advisory Role: Alkermes, Amgen, Bactonix, BeiGene, BioAtla, Bristol-Myers Squibb, Esai Biotech, Genentech, Georgiamune, GigaGen, GlaxoSmithKline, Grit Biotechnology, Idera, Immunocore, Incyte, Instil Bio, IO Biotech, Iovance, Janssen, KSQ Therapeutics, Merck, Moderna Therapeutics, NGM Biopharmaceuticals, Novartis, Obsidian Therapeutics, Pfizer, Regeneron, Roche, Sanofi, Seattle Genetics, Tempus, Vial, and Zelluna
Speakers' Bureau: Bristol-Myers Squibb, Immunocore, Novartis, Pfizer, and Regeneron
Research Funding: Aduro Biotech, Akeso Biopharma, Amgen, Arcus Biosciences, Bioatla, Bristol-Myers Squibb, CytomX Therapeutics, Exelixis, Genentech, GlaxoSmithKline, Idera, Immunocore, Incyte, Iovance Biotherapeutics, Merck, Merck Serono, Moderna Therapeutics, NextCure, Novartis, Pfizer, Regeneron, Roche, Sanofi, Seattle Genetics, Torque, and Zelluna
No conflicts to report
No conflicts to report
Consulting/Advisory: Adaptive Biotechnologies, CStone Pharmaceuticals, Dragonfly Therapeutics, Genocea Biosciences, and Incyte
Research Funding: Aduro Biotech, Amgen, Bristol-Myers Squibb, and Corvus Pharmaceuticals;
Intellectual Property: GVAX (and has received yearly milestone payments for it)
Travel, Accommodations, or Other Expenses: Bristol-Myers Squibb, Genocea Biosciences, and MedImmune
Other Relationships: Dragonfly Therapeutics
Honoraria: CMP Healthcare Oncology Publishing, The ASCO Post
Consulting or Advisory Role: CommGeniX, International Genetics, AlphaSights
Travel, Accommodations, Expenses: Hospital Association of PA, Bristol-Myers Squibb
Other Relationships: BP
Research Funding: Pfizer, Amgen, Bristol-Myers Squibb, Novartis
Consulting or Advisory Role: BMS, HUTCHMED, Ipsen, Isotope Technologies Munich SE (ITM), and Novartis (Advanced Accelerator Applications)
Research Funding: Novartis (Advanced Accelerator Applications) and RayzeBio
No conflicts to report
Leadership: Cellworks, LifeLink
Consulting or Advisory Role: Integra
Consulting or Advisory Role: Magellan Health
Consulting/Advisory Board: AstraZeneca
Advisory Board: Novocure, Guardant Health, Takeda
Honoraria: Genentech/Roche, Amgen, Bayer/Onyx, Taiho Pharmaceutical, Caris Life Sciences, Celgene
Consulting or Advisory Role: Genentech/Roche, Amgen, Bayer/Onyx, Taiho Pharmaceutical, Caris Life Sciences, Celgene
Speakers' Bureau: Genentech/Roche, Amgen, Bayer/Onyx
Research Funding: Bayer/Onyx, Genentech/Roche, Pfizer, Amgen, Boehringer Ingelheim, MedImmune
Honoraria: Advaxis
Consulting or Advisory Role: Merck, NextCure, and Novartis
Research Funding: Fujifilm, Immunogen, Leap Therapeutics, Merck, Mersana, Novartis, SQZ Biotechnologies, Syndax, and Tesaro
Travel, Accommodations, Other Expenses: AstraZeneca
Honoraria: Advanced Accelerator Applications, Astellas Colombia, Astellas Scientific and Medical Affairs Inc, AstraZeneca, Bayer, Clovis Oncology, Exelixis, Genentech, Janssen, Merck, Myovant Sciences, Pfizer, Sanofi, and Telix Pharmaceuticals
Consulting or Advisory Role: Advanced Accelerator Applications, Astellas Pharma, AstraZeneca, Bayer, Blue Earth Diagnostics, Exelixis, Janssen, Lantheus Medical Imaging, Merck, Myovant Sciences, Myriad Genetics, Novartis, and Sanofi
Research Funding: Astellas Scientific and Medical Affairs Inc, AstraZeneca, Bayer, Dendreon, Genentech, Myovant Sciences, Sanofi, and Seattle Genetics/Astellas
Travel, Accommodations, Expenses: Sanofi and Telix Pharmaceuticals
No conflicts to report
Consulting or Advisory Role: Seattle Genetics
Consulting or Advisory Role: Boehringer Ingelheim
Research Funding: Boehringer Ingelheim, AstraZeneca, Exelixis, Novartis, MedImmune, Merck, Genentech/Roche, Lilly, Bayer
Consulting or Advisory Role: Gerson Lehrman Group, Caris Life Sciences
Stock & Other Ownership Interests: AuraSense LLC, Nanosphere Inc.
Honoraria: Celgene, Pharmacyclics, Janssen Biotech, Valeant Pharmaceuticals International
Consulting or Advisory Role: Celgene, Genetech Health Practices Consulting, Seattle Genetics
Research Funding: Celgene, Lilly
Research Funding: Eisai, Pfizer
Institutional Research Funding: AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Genentech/Roche, Lilly, Merck, and Pfizer
Honoraria: Pfizer, Amgen, Bristol-Myers Squibb, Tesaro
Consulting or Advisory Role: Amgen, Bristol-Myers Squibb, Pfizer, Helsinn Therapeutics
Speakers' Bureau: Genentech/Roche
Research Funding: Helsinn Therapeutics
Honoraria: Genomic Health, Eisai, Genentech/Roche, Celgene
Consulting or Advisory Role: Genentech/Roche, Pfizer, Celgene, Eisai
Speakers' Bureau: Genomic Health, Eisai, Genentech/Roche, Celgene
Research Funding: Bayer
Travel, Accommodations, Expenses: Genomic Health, Genentech/Roche, Eisai, Celgene
Consulting or Advisory Role: 3M, BlueCross and BlueShield of Michigan, Amgen
Employment: UpToDate
Patents, Royalties, & Other Intellectual Property: UpToDate, Royalties from Oxford Textbook of Cancer Communication, co-editor
Travel, Accommodations, Expenses: GEOMC, Inc. Seoul, Korea
No conflicts to report as of 7/13/18
No conflicts to report
No conflicts to report
No conflicts to report
Consulting or Advisory Role: Genomic Health
Travel, Accommodations, Expenses: TEVA, Tel Aviv
Research Funding: Astellas Pharma, Chimerix, and Merck
Honoraria: Bayer, Bristol-Myers Squibb, Fresenius Kabi, Roche, Pfizer
Consulting or Advisory Role: Bayer, Pfizer
Speakers' Bureau: Bayer, Daiichi Sankyo
Travel, Accommodations, Expenses: Pfizer
No conflicts to report
No conflicts to report
No conflicts to report
Leadership: IBA - Ion Beam Applications
Consulting or Advisory Role: IBA
Travel, Accommodations, Expenses: IBA
Consulting or Advisory Role: AstraZeneca, Amgen, Boehringer Ingelheim
Speakers' Bureau: Roche
No conflicts to report
No conflicts to report
Honoraria: Roche, Novartis, Pfizer, MSD Oncology, Lilly
Research Funding: Roche
Travel, Accommodations, Expenses: Celgene, MSD Oncology, Roche, Novartis
No conflicts to report
Consulting or Advisory Role: Bristol-Myers Squibb, AstraZeneca, MSD Oncology
Speakers' Bureau: MSD Oncology, Bristol-Myers Squibb
Travel, Accommodations, Expenses: Bristol-Myers Squibb, Pfizer
